Promega Corporation

pAdVAntage™ Vector

Co-transfection of mammalian cells with the pAdVAntage™ Vector enhances transient protein expression in a variety of cell types by increasing translation initiation.

Transfection of mammalian cells with an expression vector often results in suboptimal expression of the protein of interest. Double-stranded RNA (dsRNA) generated during transfection is thought to activate the dsRNA-activated inhibitor (DAI), one of several enzymes involved in the host cell's antiviral defense system. DAI phosphorylates the translation initiation factor eIF-2, halting translation and therefore protein production.

However, DA...

Expand to Read More »

  • Share
  • Print
  • Email
  • Products
  • Specifications
  • Figures & Tables
  • Product Resources
  • Patents & Disclaimers
  • Prices valid for Australian customers only
Product Size Conc. Catalog # *List Price Order QTY Add to Cart

pAdVAntage™ Vector

Close Window

pAdVAntage™ Vector

 Components

  • pAdVAntage™ Vector

    E171A1 x 20μg
Close Window
  • This product can be added to a

  • Helix Freezer

This product is available through the Promega Helix onsite stocking program in a –20°C Helix Freezer. The program offers numerous convenient solutions to meet your lab's needs. Helix Freezers are available in two sizes: 5.7 cubic ft. or 9.7 cubic ft.


Click here to learn more about the Helix Collection »


Already a Helix Customer?

Login to request to add this product to your Helix »


20μg
- E1711 A$ 167.00 Add to cart


You Also May Be Interested In

GenBank®/EMBL Accession Number

pAdVAntage™ Vector Accession Number U47294; pAdVAntage™ Vector sequence text file.

Storage Conditions

Store at –20°C.

For product intended use please see Patents & Disclaimers tab.

Figures

pAdVAntage Vector.Figure 1. pAdVAntage™ Vector.

Use Restrictions

E1711 For Research Use Only. Not for Use in Diagnostic Procedures.

  • Warning
  • It appears that you have Javascript disabled. Our website requires Javascript to function correctly. Please enable Javascript to experience our website.